Vanguard Amends Eli Lilly Stake, Remains Key Passive Investor

TL;DR

**Vanguard still owns a big chunk of Eli Lilly, signaling continued institutional confidence.**

AI Summary

The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, indicating its ownership of Eli Lilly & Co. common stock as of December 29, 2023. This filing, an amendment number 8, shows that Vanguard continues to be a significant passive investor in Eli Lilly, holding a substantial stake. For investors, this means a large, stable institutional holder like Vanguard remains committed to Eli Lilly, which can signal confidence in the company's long-term prospects.

Why It Matters

This filing confirms Vanguard's continued significant, passive ownership in Eli Lilly, which can provide a sense of stability and institutional confidence for current and prospective shareholders.

Risk Assessment

Risk Level: low — This filing is routine for large institutional investors and indicates no immediate change in Vanguard's passive investment strategy for Eli Lilly.

Analyst Insight

Investors should note that a major institutional investor like Vanguard continues to hold a significant, passive stake in Eli Lilly, which can be a sign of long-term stability, but this filing itself doesn't suggest any immediate buying or selling action.

Key Players & Entities

• The Vanguard Group (company) — reporting person and major institutional investor
• Eli Lilly & Co. (company) — subject company whose securities are being reported
• December 29, 2023 (date) — date of event requiring the filing
• February 13, 2024 (date) — date the SC 13G/A was filed
• Pennsylvania (company) — place of organization for The Vanguard Group

Forward-Looking Statements

• Vanguard will maintain its passive investment strategy in Eli Lilly for the foreseeable future. (The Vanguard Group) — high confidence, target: 2025-12-31
• Eli Lilly's stock will continue to be viewed favorably by large institutional investors due to its strong market position. (Eli Lilly & Co.) — medium confidence, target: 2024-12-31

FAQ

From the Filing

0001104659-24-020827.txt : 20240213 0001104659-24-020827.hdr.sgml : 20240213 20240213170442 ACCESSION NUMBER: 0001104659-24-020827 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-17885 FILM NUMBER: 24628420 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: VANGUARD GROUP INC CENTRAL INDEX KEY: 0000102909 ORGANIZATION NAME: IRS NUMBER: 231945930 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 BUSINESS PHONE: 6106691000 MAIL ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 SC 13G/A 1 tv0827-elilillyco.htm SCHEDULE 13G/A elilillyco SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer:  Eli Lilly & Co Title of Class of Securities:  Common Stock CUSIP Number:  532457108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on the following page(s))     13G CUSIP No.:  532457108 1.  NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON The Vanguard Group - 23-1945930 2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP A.  B.  X 3.  SEC USE ONLY 4.  CITIZENSHIP OF PLACE OF ORGANIZATION Pennsylvania (For questions 5-8, report the number of shares beneficially owned by each reporting person with:) 5.  SOLE VOTING POWER 0 6.  SHARED VOTING POWER 1,084,305 7.  SOLE DISPOSITIVE POWER 68,104,377 8.  SHARED DISPOSITIVE POWER 3,500,319 9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 71,604,696 10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES N/A 11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.54% 12.  TYPE OF REPORTING PERSON IA     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Act of 1934 Item 1(a) - Name of Issuer: Eli Lilly & Co Item 1(b) - Address of Issuer's Principal Executive Offices: Lilly Corporate Center Indianapolis, IN 46285 Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930 Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355 Item 2(c) – Citizenship: Pennsylvania Ite